Marco Meglio

Patients were more affected by seizure cluster control and need for additional midazolam dosing than post-dose somnolence.

Data suggests that treatment with cannabidiol is associated with other benefits besides a decrease in seizure frequency.

Adjunctive cenobamate demonstrated a good tolerability and safety profile, as well as sustained efficacy, in patients with uncontrolled focal seizures.

Fenfluramine oral solution is currently being evaluated by the FDA for the treatment of seizures associated with Dravet syndrome.

Patients treated with intranasal midazolam who were on enzyme-inducing AEDs experienced numerically lower treatment-emergent adverse events.

The American Epilepsy Society recognized several members from its clinical and research communities for their outstanding contributions to the field of epilepsy.

An analysis of 2 different doses of intranasal diazepam showed consistent safety and tolerability results for repeat dosing

Although there are gaps in knowledge, investigators see potential in telemedicine for other neurologic disorders beyond stroke.

Results of the phase 3 ACHIEVE I trial showed a high percentage of patients were free from their most bothersome symptoms 2 hours post dose.

The director emeritus of the Cleveland Clinic Lou Ruvo Center for Brain Health discussed the significance of the HARMONY study findings and what they mean for the future treatment of dementia-related psychosis.

The drug was proven to be efficacious and generally well tolerated in adults with newly diagnosed epilepsy.

Patients who were administered levetiracetam, fosphenytoin, or valproate saw similar improvements in seizure reduction and responsiveness.

Top line results from the phase 3 trial of sovateltide in patients with acute cerebral ischemic stroke are expected by mid-2020.

No progressive or delayed complications of treatment were recorded after 3 years in patients with essential tremor who underwent focused ultrasound.

The private-public partnership aims to share patient data in hopes of uncovering new biomarkers related to Parkinson disease.

Fenfluramine is set for priority review by the FDA with a PDUFA date of March 25, 2020.

Results from the phase 3 EVOLVE-MS-2 study demonstrate superior tolerability for now-approved diroximel fumarate compared to dimethyl fumarate.

The phase 1/2 trial seeks to will assess the safety and efficacy of mesenchymal stem cells for the treatment of Alzheimer disease.

James Leverenz, MD, director of the Lou Ruvo Center for Brain Health at Cleveland Clinic, sat down to discuss the challenges faced in diagnosing Lewy body dementia.

No progressive or delayed complications of treatment were recorded after 3 years in patients with essential tremor who underwent focused ultrasound.

A study comparing 2 doses of minocycline falls short as the drug failed to slow progression of cognitive or functional decline in people with AD.

A lower target for low-density lipoprotein is associated with a greater reduction in cardiovascular events after ischemic stroke over a higher LDL target.

Benjamin Walter, MD, medical director of the Deep Brain Stimulation Program at Cleveland Clinic shared his personal experience with deep brain stimulation and focused ultrasound and the potential of the procedures.

Data from a new study demonstrates valbenazine’s ability to effectively reduce TD symptoms over a long-term period.

Patients in small-scale trial experienced a drastic reduction in monthly headache days after just 1 dose of erenumab.

Study data demonstrates that treatment with satralizumab reduces risk of relapses in patients with neuromyelitis optica spectrum disorder.

Patients with spinal muscular atrophy types 2 or 3 saw improvements in motor function after receiving risdiplam; data will be presented at an upcoming medical congress.

EIP Pharma also announced results from the REVERSE-SD study that examined neflamapimod in early stage Alzheimer disease.

The robotic platform used in various neurosurgeries was identified for a class 1 recall due to a software error which can lead to robotic arm malfunction.

The phase 2/3 trials will end after a futility analysis suggested that the drug is not likely to show a clinical benefit.